PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27325144-11	2018	In western blot analysis, montelukast was able to suppress LPS-induced MAPK-phospho-p38 and NF-kappaB-phospho-p65 expression.	montelukast	26-37	nuclear factor kappa B subunit 1	Homo sapiens	92-101	
34004207-5	2021	Montelukast can ameliorate extra-pulmonary manifestations in Covid-19 either directly through blocking of Cys-LTRs in different organs or indirectly through inhibition of the NF-kappaB signaling pathway.	montelukast	0-11	nuclear factor kappa B subunit 1	Homo sapiens	175-184	
27325144-12	2018	CONCLUSION: Montelukast suppressed LPS-induced M2-related cytokines and chemokines in alternatively activated macrophages, and the effects might be mediated through the MAPK-p38 and NF-kappaB-p65 pathways.	montelukast	12-23	nuclear factor kappa B subunit 1	Homo sapiens	182-191	
32949526-3	2020	An approved asthma drug, montelukast, has been found to modulate the activity of NF-kappaB, and result in a corresponding decrease in proinflammatory mediators.	montelukast	25-36	nuclear factor kappa B subunit 1	Homo sapiens	81-90	
32949526-4	2020	Herein, we hypothesize that repurposing montelukast to suppress NF-kappaB activation will result in an attenuation of proinflammatory mediators and a decrease in cytokine production, thereby leading to a reduction in symptom severity and to improved clinical outcomes in patients with Coronavirus 2019 (COVID-19).	montelukast	40-51	nuclear factor kappa B subunit 1	Homo sapiens	64-73	
18325031-2	2008	In this study, we aimed to investigate the effect of montelukast on nuclear factor (NF)-kappaB-associated histone acetylation activity in phorbol myristate acetate (PMA)-differentiated U937 cells.	montelukast	53-64	nuclear factor kappa B subunit 1	Homo sapiens	68-94	
23954527-7	2013	Montelukast treatment prevented IL-8 release and heterologous beta2-adrenoceptor desensitization in human BSMC exposed to monocyte-derived MPs by blocking NF-kappaB nuclear translocation.	montelukast	0-11	nuclear factor kappa B subunit 1	Homo sapiens	155-164	
15984600-9	2005	CONCLUSIONS: These findings suggest that high doses of montelukast modulate the production of IL-6, TNF-alpha, and MCP-1 through the inhibition of NF-kappaB activation.	montelukast	55-66	nuclear factor kappa B subunit 1	Homo sapiens	147-156	
15984600-2	2005	However, the action of montelukast in terms of nuclear factor KB (NF-kappaB) activation and the production of proinflammatory molecules is unknown.	montelukast	23-34	nuclear factor kappa B subunit 1	Homo sapiens	62-64	
15984600-2	2005	However, the action of montelukast in terms of nuclear factor KB (NF-kappaB) activation and the production of proinflammatory molecules is unknown.	montelukast	23-34	nuclear factor kappa B subunit 1	Homo sapiens	66-75	
15984600-4	2005	METHODS: We examined whether montelukast inhibits the activation of NF-kappaB, a transcription factor that regulates the expression of proinflammatory molecules.	montelukast	29-40	nuclear factor kappa B subunit 1	Homo sapiens	68-77	
15984600-6	2005	RESULTS: Flow cytometry demonstrated that montelukast inhibited NF-kappaB activation in THP-1 cells in a dose-related manner.	montelukast	42-53	nuclear factor kappa B subunit 1	Homo sapiens	64-73